High Variation in Expert Assessment of Peritoneal Malignancy
Surgeons face significant interobserver variation in evaluating peritoneal lesions despite their experience.
Newsletter
Cytoreductive Surgery & Peritoneum
Every new paper in this field, in your inbox.
Gastric Cancer Peritoneal Metastasis Management Consensus Established
New guidelines for managing gastric cancer peritoneal metastasis (gcpm) offer surgeons a pathway to improve patient outcomes.
PIPAC Treatment Linked to Longer Survival in Unresectable Malignancies
More treatments with pressurized intraperitoneal aerosol chemotherapy (PIPAC) lead to better survival outcomes for patients with unresectable peritoneal surface malignancies (PSMs).
Laparoscopic surgery yields similar outcomes for colorectal peritoneal metastases.
Consider laparoscopic cytoreductive surgery for suitable patients to enhance recovery without compromising oncologic effectiveness.
New Consensus Guidelines for Peritoneal Mesothelioma Care
A recent consensus on managing peritoneal mesothelioma reaffirms critical treatment strategies.
Cytoreductive Surgery Best Practices for Peritoneal Malignancies
New guidelines for cytoreductive surgery (CRS) emphasize improved patient outcomes through standardized techniques.
CRS/HIPEC Improves Survival in Low-Grade Appendiceal Carcinoma
CRS/HIPEC significantly enhances survival for select low-grade appendiceal carcinoma patients with peritoneal and parenchymal metastases.
Prophylactic CRS and HIPEC Elevate Outcomes in Appendiceal Cancer
Prophylactic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) offers significantly improved survival for patients with perforated appendiceal adenocarcinoma.
Gastric Cancer Treatment Shift: Prioritizing Patient Outcomes
Gastric cancer with peritoneal metastases is rising, especially in younger patients, highlighting the urgent need for better outcomes.
Efficacy of HIPEC After Laparoscopic Gastrectomy in Gastric Cancer
Laparoscopic gastrectomy plus hyperthermic intraperitoneal chemotherapy (HIPEC) improves outcomes for gastric cancer patients with positive peritoneal lavage cytology.